Osimertinib Treats CNS Metastases in NSCLC.

Abstract:

:The EGFR inhibitor osimertinib may be an effective therapy for patients with untreated non-small cell lung cancer who have brain metastases. In a recent study, the drug extended median progression-free survival and increased objective response rates compared with the first-generation EGFR inhibitors gefitinib and erlotinib.

journal_name

Cancer Discov

journal_title

Cancer discovery

authors

doi

10.1158/2159-8290.CD-NB2018-121

subject

Has Abstract

pub_date

2018-11-01 00:00:00

pages

OF3

issue

11

eissn

2159-8274

issn

2159-8290

pii

2159-8290.CD-NB2018-121

journal_volume

8

pub_type

评论,新闻
  • Arvinas, Pfizer Team Up on PROTACs.

    abstract::Biotechnology startup Arvinas is developing proteolysis-targeting chimeras (PROTAC) that combat cancer by degrading disease-causing proteins. The company's first PROTACs will target prostate and breast cancers, and a recent deal with Pfizer will allow Arvinas to develop PROTACs for other cancer types. ...

    journal_title:Cancer discovery

    pub_type: 新闻

    doi:10.1158/2159-8290.CD-NB2018-015

    authors:

    更新日期:2018-04-01 00:00:00

  • An ADC for Triple-Negative Breast Cancer.

    abstract::A phase II study indicates that sacituzumab govitecan (IMMU-132), a Trop-2-specific antibody linked to the irinotecan metabolite SN-38, prolongs the progression-free survival of patients with advanced triple-negative breast cancer. IMMU-132 is well tolerated, causing fewer and more manageable side effects than irinote...

    journal_title:Cancer discovery

    pub_type: 新闻

    doi:10.1158/2159-8290.CD-NB2015-162

    authors:

    更新日期:2016-01-01 00:00:00

  • Biomarkers define distinct types of diffuse glioma.

    abstract::Three genetic markers performed far better than histologic criteria to classify diffuse low-grade gliomas, laying the foundation for molecular diagnosis of this heterogeneous group of brain tumors. ...

    journal_title:Cancer discovery

    pub_type: 新闻

    doi:10.1158/2159-8290.CD-NB2015-092

    authors:

    更新日期:2015-08-01 00:00:00

  • Anatomic Gene Expression Atlas Fuels Glioblastoma Discovery.

    abstract::The Ivy Glioblastoma Atlas provides detailed information about genes expressed in different anatomic regions of human brain tumors. Researchers are already drawing upon the resource to identify novel therapeutic targets for this deadly cancer. ...

    journal_title:Cancer discovery

    pub_type: 新闻

    doi:10.1158/2159-8290.CD-NB2018-066

    authors:

    更新日期:2018-07-01 00:00:00

  • Triple-acting drug boosts prostate cancer survival.

    abstract::A phase III trial of the agent MDV3100 in men with advanced prostate cancer previously treated with docetaxel-based chemotherapy is being stopped early so that the drug can be given to all participants. ...

    journal_title:Cancer discovery

    pub_type: 新闻

    doi:10.1158/2159-8290.CD-NB111711OL-09

    authors:

    更新日期:2011-12-01 00:00:00

  • Can the Help Match the Hype? KRASG12C-Specific Inhibitors and Beyond.

    abstract::Hallin and colleagues demonstrate the preclinical activity of the KRASG12C-specific inhibitor MRTX849 in a series of in vitro and in vivo studies with supporting pilot clinical efficacy. Variable responsiveness despite effective KRASG12C inhibition highlights both the promise and potential need for combinatorial strat...

    journal_title:Cancer discovery

    pub_type: 评论,杂志文章

    doi:10.1158/2159-8290.CD-19-1255

    authors: Klempner SJ,Hata AN

    更新日期:2020-01-01 00:00:00

  • New Method Enables Development of Customized Vasculature in Organoids.

    abstract::Transduction of ETV2 restored blood vessel-forming capabilities to mature human endothelial cells. ...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-RW2020-135

    authors:

    更新日期:2020-11-01 00:00:00

  • Neoantigen Quality Predicts Immune Response, Survival.

    abstract::A new mathematical model finds that tumor neoantigen quality trumps quantity when it comes to predicting response to immunotherapy and the likelihood of long-term survival among patients with cancer. ...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-NB2017-165

    authors:

    更新日期:2018-01-01 00:00:00

  • YY1 Facilitates Enhancer-Promoter Contacts to Promote Gene Expression.

    abstract::YY1 preferentially occupies active enhancers and promoters and forms dimers to promote DNA looping. ...

    journal_title:Cancer discovery

    pub_type: 评论,杂志文章

    doi:10.1158/2159-8290.CD-RW2017-233

    authors:

    更新日期:2018-02-01 00:00:00

  • Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma.

    abstract:UNLABELLED:Next-generation sequencing was used to identify Notch mutations in a large collection of diverse solid tumors. NOTCH1 and NOTCH2 rearrangements leading to constitutive receptor activation were confined to triple-negative breast cancers (TNBC; 6 of 66 tumors). TNBC cell lines with NOTCH1 rearrangements associ...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-13-0830

    authors: Stoeck A,Lejnine S,Truong A,Pan L,Wang H,Zang C,Yuan J,Ware C,MacLean J,Garrett-Engele PW,Kluk M,Laskey J,Haines BB,Moskaluk C,Zawel L,Fawell S,Gilliland G,Zhang T,Kremer BE,Knoechel B,Bernstein BE,Pear WS,Liu

    更新日期:2014-10-01 00:00:00

  • Protective effect of aspirin associated with SNP.

    abstract::According to findings of a study in the Journal of the National Cancer Institute, people with a single-nucleotide polymorphism on chromosome 8q24 who regularly use aspirin can cut their risk of colorectal cancer by about half. ...

    journal_title:Cancer discovery

    pub_type: 新闻

    doi:10.1158/2159-8290.CD-NB2014-011

    authors:

    更新日期:2014-03-01 00:00:00

  • Pazopanib outscores sunitinib on tolerability.

    abstract::In a phase III trial for patients with metastatic renal cell carcinoma, pazopanib and sunitinib offered comparable progression-free survival, but pazopanib scored higher on quality-of-life indices. ...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-NB2013-131

    authors:

    更新日期:2014-01-01 00:00:00

  • Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations.

    abstract::Loss-of-function mutations in JAK1/2 can lead to acquired resistance to anti-programmed death protein 1 (PD-1) therapy. We reasoned that they may also be involved in primary resistance to anti-PD-1 therapy. JAK1/2-inactivating mutations were noted in tumor biopsies of 1 of 23 patients with melanoma and in 1 of 16 pati...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-16-1223

    authors: Shin DS,Zaretsky JM,Escuin-Ordinas H,Garcia-Diaz A,Hu-Lieskovan S,Kalbasi A,Grasso CS,Hugo W,Sandoval S,Torrejon DY,Palaskas N,Rodriguez GA,Parisi G,Azhdam A,Chmielowski B,Cherry G,Seja E,Berent-Maoz B,Shintaku IP,L

    更新日期:2017-02-01 00:00:00

  • A combined epigenetic therapy equals the efficacy of conventional chemotherapy in refractory advanced non-small cell lung cancer.

    abstract::A new study by Juergens and colleagues provides the first successful example of a combined epigenetic therapy capable of achieving results similar to those of conventional chemotherapy in refractory metastatic non-small cell lung cancer. Furthermore, the authors describe interesting blood-based DNA methylation biomark...

    journal_title:Cancer discovery

    pub_type: 评论,杂志文章

    doi:10.1158/2159-8290.CD-11-0271

    authors: Rodríguez-Paredes M,Esteller M

    更新日期:2011-12-01 00:00:00

  • Measuring oncogenic signaling pathways in cancer with PET: an emerging paradigm from studies in castration-resistant prostate cancer.

    abstract:UNLABELLED:As parallel advances in cancer biology and drug development continue to elevate the role of targeted therapies in oncology, the need for imaging biomarkers that systematically measure the biology associated with therapeutic intervention has become more urgent. Although the molecular imaging community has a c...

    journal_title:Cancer discovery

    pub_type: 杂志文章,评审

    doi:10.1158/2159-8290.CD-12-0178

    authors: Evans MJ

    更新日期:2012-11-01 00:00:00

  • Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset.

    abstract:UNLABELLED:Identifying genetic alterations that prime a cancer cell to respond to a particular therapeutic agent can facilitate the development of precision cancer medicines. Cancer cell-line (CCL) profiling of small-molecule sensitivity has emerged as an unbiased method to assess the relationships between genetic or c...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-15-0235

    authors: Seashore-Ludlow B,Rees MG,Cheah JH,Cokol M,Price EV,Coletti ME,Jones V,Bodycombe NE,Soule CK,Gould J,Alexander B,Li A,Montgomery P,Wawer MJ,Kuru N,Kotz JD,Hon CS,Munoz B,Liefeld T,Dančík V,Bittker JA,Palmer M,

    更新日期:2015-11-01 00:00:00

  • E-cigarettes Best Other Cessation Tools.

    abstract::Electronic cigarettes (e-cigarettes) may be an effective tool for smoking cessation. In a randomized trial, researchers found that 18% of those assigned to use e-cigarettes were smoke-free after a year, compared with 9.9% of those assigned to nicotine replacement therapies such as patches and gum. However, those in th...

    journal_title:Cancer discovery

    pub_type: 评论,新闻

    doi:10.1158/2159-8290.CD-NB2019-018

    authors:

    更新日期:2019-04-01 00:00:00

  • Advancing the Precision Medicine Initiative.

    abstract::The NIH has approved the framework to build a national research cohort of 1 million Americans, a key part of President Obama's Precision Medicine Initiative. ...

    journal_title:Cancer discovery

    pub_type: 新闻

    doi:10.1158/2159-8290.CD-NB2015-146

    authors:

    更新日期:2015-12-01 00:00:00

  • Clonal evolution: multiregion sequencing of esophageal adenocarcinoma before and after chemotherapy.

    abstract::It is possible to decipher the clonal architecture of a tumor and the sequence in which cancer clones acquire genomic alterations through multiregion sequencing (M-seq). Serial evaluation of tumor specimens through M-seq can provide valuable information on the molecular basis of resistance to therapy. ...

    journal_title:Cancer discovery

    pub_type: 评论,杂志文章

    doi:10.1158/2159-8290.CD-15-0739

    authors: Devarakonda S,Govindan R

    更新日期:2015-08-01 00:00:00

  • Intense Radiotherapy Slows Prostate Cancer Growth.

    abstract::Adding stereotactic ablative radiotherapy (SABR) to standard treatment slowed 6-month disease progression in men with hormone-sensitive metastatic prostate cancer, allowing them to delay androgen deprivation therapy, according to findings from the phase II ORIOLE trial. Larger studies are needed to determine if SABR, ...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-NB2020-034

    authors:

    更新日期:2020-06-01 00:00:00

  • Gain-of-Function Genetic Alterations of G9a Drive Oncogenesis.

    abstract::Epigenetic regulators, when genomically altered, may become driver oncogenes that mediate otherwise unexplained pro-oncogenic changes lacking a clear genetic stimulus, such as activation of the WNT/β-catenin pathway in melanoma. This study identifies previously unrecognized recurrent activating mutations in the G9a hi...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-19-0532

    authors: Kato S,Weng QY,Insco ML,Chen KY,Muralidhar S,Pozniak J,Diaz JMS,Drier Y,Nguyen N,Lo JA,van Rooijen E,Kemeny LV,Zhan Y,Feng Y,Silkworth W,Powell CT,Liau BB,Xiong Y,Jin J,Newton-Bishop J,Zon LI,Bernstein BE,Fish

    更新日期:2020-07-01 00:00:00

  • Nod for Atezolizumab in Advanced Bladder Cancer.

    abstract::The FDA approved atezolizumab to treat advanced bladder cancer when cisplatin chemotherapy is contraindicated. The approval offers a potentially more effective alternative to carboplatin-based chemotherapy for frail, elderly patients. ...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-NB2017-064

    authors:

    更新日期:2017-06-01 00:00:00

  • Novel Mitochondrial Mechanisms of Cytarabine Resistance in Primary AML Cells.

    abstract:: Farge and colleagues describe a novel in vivo approach to identify and study primary acute myeloid leukemia (AML) cells that persist in the marrow after chemotherapy. They discovered that AML cells that persist in the mouse marrow after treatment with cytarabine have increased oxidative phosphorylation and that i...

    journal_title:Cancer discovery

    pub_type: 评论,杂志文章

    doi:10.1158/2159-8290.CD-17-0476

    authors: Schimmer AD

    更新日期:2017-07-01 00:00:00

  • STATe-of-the-art approach: using oligonucleotide decoys to target the "undruggable".

    abstract::Sen and colleagues have shown for the first time the clinical application of an oligonucleotide decoy targeting the oncogenic transcription factor STAT3 for the treatment of head and neck tumors. Intratumoral injection of decoy effectively reduced the activity of STAT3 as evidenced by a decrease in several of its tran...

    journal_title:Cancer discovery

    pub_type: 评论,杂志文章

    doi:10.1158/2159-8290.CD-12-0310

    authors: Koppikar P,Bromberg J

    更新日期:2012-08-01 00:00:00

  • NK Cells Mediate T-cell Inflammation in the Tumor Microenvironment.

    abstract::IFNγ-producing NK cells induced TME remodeling and orchestrated T cell-mediated tumor control. ...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-RW2020-174

    authors:

    更新日期:2020-12-04 00:00:00

  • ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors.

    abstract:UNLABELLED:ARID1A, SWI/SNF chromatin remodeling complex subunit, is a recently identified tumor suppressor that is mutated in a broad spectrum of human cancers. Thus, it is of fundamental clinical importance to understand its molecular functions and determine whether ARID1A deficiency can be exploited therapeutically. ...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-14-0849

    authors: Shen J,Peng Y,Wei L,Zhang W,Yang L,Lan L,Kapoor P,Ju Z,Mo Q,Shih IeM,Uray IP,Wu X,Brown PH,Shen X,Mills GB,Peng G

    更新日期:2015-07-01 00:00:00

  • Two Unique Glioma Subtypes Revealed.

    abstract::A comprehensive analysis of 1,122 diffuse glioma samples from The Cancer Genome Atlas has revealed two new subtypes of this common brain cancer, with molecular and clinical features that diverge from the norm. The study findings also support the use of DNA methylation profiles to improve glioma classification and trea...

    journal_title:Cancer discovery

    pub_type: 新闻

    doi:10.1158/2159-8290.CD-NB2016-022

    authors: Poh A

    更新日期:2016-04-01 00:00:00

  • ZNF365 promotes stability of fragile sites and telomeres.

    abstract::Critically short telomeres activate cellular senescence or apoptosis, as mediated by the tumor suppressor p53, but in the absence of this checkpoint response, telomere dysfunction engenders chromosomal aberrations and cancer. Here, analysis of p53-regulated genes activated in the setting of telomere dysfunction identi...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-12-0536

    authors: Zhang Y,Shin SJ,Liu D,Ivanova E,Foerster F,Ying H,Zheng H,Xiao Y,Chen Z,Protopopov A,Depinho RA,Paik JH

    更新日期:2013-07-01 00:00:00

  • Detection of Enhancer-Associated Rearrangements Reveals Mechanisms of Oncogene Dysregulation in B-cell Lymphoma.

    abstract:UNLABELLED:B-cell lymphomas frequently contain genomic rearrangements that lead to oncogene activation by heterologous distal regulatory elements. We used a novel approach called "pinpointing enhancer-associated rearrangements by chromatin immunoprecipitation," or PEAR-ChIP, to simultaneously map enhancer activity and ...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-15-0370

    authors: Ryan RJ,Drier Y,Whitton H,Cotton MJ,Kaur J,Issner R,Gillespie S,Epstein CB,Nardi V,Sohani AR,Hochberg EP,Bernstein BE

    更新日期:2015-10-01 00:00:00

  • A FATal Combination: Fibroblast-Derived Lipids and Cancer-Derived Autotaxin Promote Pancreatic Cancer Growth.

    abstract::In this issue of Cancer Discovery, Auciello and colleagues find that in the pancreatic cancer microenvironment activated fibroblasts secrete specific lipids that provide a source of biomass production and signaling molecules for cancer cells, fueling their proliferation and migration. Targeting of this stromal-tumor m...

    journal_title:Cancer discovery

    pub_type: 评论,杂志文章

    doi:10.1158/2159-8290.CD-19-0273

    authors: Biffi G,Tuveson DA

    更新日期:2019-05-01 00:00:00